Novo Nordisk Puts 5 Billion DKK Behind Its Stock as Pipeline Wins Offset Cyber Setback

UK approves oral Wegovy for obesity; Zenagamtide shows strong diabetes data; CagriSema mixed but on track; cyber breach contained. Stock undervalued?

The Danish pharmaceutical giant has endured a week of stark contrasts, threading clinical breakthroughs, a regulatory milestone, and an unwelcome digital intrusion. While a share buyback programme worth up to 15 billion DKK signals management’s belief in the underlying business, the stock continues to trade well below its highs, weighed down by pricing pressure and intensifying competition.

Oral Wegovy Cleared in Britain

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the oral version of Wegovy — a 25 mg daily GLP-1 pill — for weight management in adults. This marks the first approval of an oral semaglutide formulation for obesity in Europe. Clinical data from the OASIS 4 trial showed patients lost an average of 16.6% of their body weight, with roughly one in three exceeding 20% reduction. With around 15 million obese adults in Britain, analysts expect the drug to become available on private prescription within weeks, potentially expanding the total addressable market rather than merely cannibalising existing injectable users.

Zenagamtide Steals the Spotlight

At the American Diabetes Association’s annual meeting in New Orleans, Novo Nordisk showcased a pipeline candidate that generated genuine excitement. Zenagamtide, a novel drug in Phase 2 development for type 2 diabetes, delivered a 1.71 percentage-point reduction in HbA1c at the highest 40 mg dose over 36 weeks. Nearly 89% of patients in that arm hit the clinically meaningful threshold of below 7%. The treatment also drove 14.6% weight loss. Phase 3 trials are scheduled to begin in the second half of 2026, with initial data not expected before 2028.

CagriSema Advances Despite Setback

The much-watched CagriSema programme continues to generate both promise and frustration. The REIMAGINE-1 study met its primary and secondary endpoints, with the 2.4 mg/2.4 mg dose yielding a 2.33 percentage-point HbA1c reduction and 12.0% weight loss versus placebo. Results were published simultaneously in The Lancet and The Lancet Diabetes & Endocrinology. However, the REDEFINE-4 head-to-head trial against Eli Lilly’s tirzepatide showed 23% weight loss after 84 weeks but failed to demonstrate non-inferiority. Novo Nordisk has also scrapped development of a single-chamber device for CagriSema, pivoting to a dual-chamber pen instead. Management insists the timeline remains unchanged: a US Food and Drug Administration submission is slated for the fourth quarter of 2026, followed by a commercial launch early in 2027.

A Cyber Intrusion Without Operational Fallout

Parallel to the good news on the regulatory and clinical fronts, Novo Nordisk disclosed an unauthorised access to its internal systems. The company said copies of certain data were taken but stressed that core operations — including manufacturing and distribution — were unaffected. No further details have been released, and the incident has not disrupted production of any marketed drugs.

Buyback Programme Steams Ahead

Since 4 February 2026, the company has repurchased approximately 18.8 million B-shares at an average price of 264.32 DKK, transactions totalling nearly 5 billion DKK. The broader share buyback authorisation runs to 15 billion DKK over twelve months. Yet the equity has barely responded: the stock closed the week at €38.03, roughly 46% below its 52-week high of €70.13 hit in June 2025. At €41.43, the 200-day moving average sits 8% above the current price, forming a technical resistance level.

Analyst Caution and a Medicare Catalyst

Goldman Sachs maintains a neutral rating on Novo Nordisk but lifted its price target from $41 to $47 following a global healthcare conference in early June. The bank believes the new oral Wegovy will primarily attract patients new to GLP-1 therapy, thereby expanding the overall market. In the US, Novo Nordisk currently commands about 39% of the GLP-1 market, trailing Eli Lilly’s 60%. A potential volume catalyst looms on 1 July 2026, when the Medicare GLP-1 Bridge Program launches. Up to 20 million beneficiaries could gain coverage, providing a significant demand boost across the sector.

Guidance and the Next Checkpoint

The operating outlook remains subdued. After first-quarter results in May, management lifted its 2026 guidance modestly: adjusted revenue growth is now expected between minus 4% and minus 12%, with adjusted operating income in a similar corridor. Pricing headwinds, political risks, and patent expiries continue to weigh. The next major milestone is the second-quarter earnings release on 5 August 2026, due before the market opens.